1[1]Nowak M, Szpakowski M, Malinowski A, et al. Serum cytokines in patients with ovarian cancer and benign ovarian cysts [J].Ginekol Pol, 2001, 72 (12A):1444～1448
2[2]Zakrzewska I, Poznanski J. Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma[J]. Pol Merkuriusz Lek, 2001, 11(63):210～213
3[3]Lee LF, Hellendall RP, Wang Y, et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration[J].J Immunol, 2000, 164(5):2769～2775
4[4]Zakrzewska I, PoznanskiJ. Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy [J].Przegl Lek, 2003, 60(1):18～20
5[5]Aoki Y, Tsuneki I, Sasaki M, et al. Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer [J]. Gynecol Obstet Invest, 2000, 50(3):207～211
6[6]Lenzi R, Rosenblum M, Verschraegen C, et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma[J]. Clin Cancer Res, 2002, 8(12):3686～3695
7[7]Pages F, Berger A, Henglein B, et al. Modulation of interleukin18 expression in human colon carcinoma:consequences for tumor immune surveillance[J]. IntJ Cancer, 1999, 84(3):326～330
8[8]Wang ZY, Gaggero A, Rubartelli A, et al. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium:evidence for defective processing in tumor cells [J]. Int J Cancer, 2002, 98(6):873～878
9[9]Freedman RS, Kudelka AP, Kavanagh JJ, et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma[J]. Clin Cancer Res, 2000, 6(6):2268～2278
10[10]Qian HN, Liu GZ, Cao SJ, et al. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-γgenes[J]. IntJ Gynecol Cancer, 2002, 12(1): 80～85
